Florence Rodgers
Biographic Data
| ID | 7990171 |
|---|---|
| NAME | Florence Rodgers |
| GIVEN NAMES | Florence |
| FAMILY NAME | Rodgers |
| SIGNATURE | RODGERS F |
| AFFILIATIONS | Royal Cornwall Hospital Trust |
| ORCID | 0000-0001-6627-1143 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
University patenting and licensing practices in the United Kingdom during the first year of the Covid-19 pandemic
Universities' decisions during technology transfer may affect affordability, accessibility, and availability of COVID-19 health technologies downstream. We investigated measures taken by the top 35 publicly funded UK universities to ensure global equitable access to COVID-19 health technologies between January and end of October 2020. We sent Freedom Of Information (FOI) requests and analysed universities’ websites, to (i) assess institutional st…
Who funded the research behind the Oxford–AstraZeneca Covid-19 vaccine
OBJECTIVES: The Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19, Vaxzevira or Covishield) builds on two decades of research and development (R&D) into chimpanzee adenovirus-vectored vaccine (ChAdOx) technology at the University of Oxford. This study aimed to approximate the funding for the R&D of ChAdOx and the Oxford-AstraZeneca vaccine and to assess the transparency of funding reporting mechanisms. METHODS: We conducted a scoping review an…
Making a Covid-19 vaccine that works for everyone
Coronavirus disease 2019 (COVID-19) mortality and morbidity have been shown to increase with deprivation and impact non-White ethnicities more severely. Despite the extra risk Black, Asian and Minority Ethnicity (BAME) groups face in the pandemic, our current medical research system seems to prioritise innovation aimed at people of European descent. We found significant difficulties in assessing baseline demographics in clinical trials for COVID-…
No prominent works on this page.
Who funded the research behind the Oxford–AstraZeneca Covid-19 vaccine
OBJECTIVES: The Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19, Vaxzevira or Covishield) builds on two decades of research and development (R&D) into chimpanzee adenovirus-vectored vaccine (ChAdOx) technology at the University of Oxford. This study aimed to approximate the funding for the R&D of ChAdOx and the Oxford-AstraZeneca vaccine and to assess the transparency of funding reporting mechanisms. METHODS: We conducted a scoping review an…
Making a Covid-19 vaccine that works for everyone
Coronavirus disease 2019 (COVID-19) mortality and morbidity have been shown to increase with deprivation and impact non-White ethnicities more severely. Despite the extra risk Black, Asian and Minority Ethnicity (BAME) groups face in the pandemic, our current medical research system seems to prioritise innovation aimed at people of European descent. We found significant difficulties in assessing baseline demographics in clinical trials for COVID-…
University patenting and licensing practices in the United Kingdom during the first year of the Covid-19 pandemic
Universities' decisions during technology transfer may affect affordability, accessibility, and availability of COVID-19 health technologies downstream. We investigated measures taken by the top 35 publicly funded UK universities to ensure global equitable access to COVID-19 health technologies between January and end of October 2020. We sent Freedom Of Information (FOI) requests and analysed universities’ websites, to (i) assess institutional st…
Medicine (3 works) · Political science (3 works) · Disease (2 works) · Internal Medicine (2 works) · Law (2 works) · Pandemic (2 works) · SARS-CoV-2 and COVID-19 Research (2 works) · 2019-20 coronavirus outbreak (1 work) · Best practice (1 work) · Business (1 work)